Paget's disease and bisphosphonates [2] (multiple letters)

New England Journal of Medicine

Volumn 353, Issue 24, 2005, Pages 2616-2618

  Liel, Yair ^a   Rendina, Domenico ^b   De Filippo, Gianpaolo ^c   Mossetti, Giuseppe ^b   Reid, Ian R ^d   Miller, Paul ^e   Hosking, David ^f  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c G RUMMO HOSPITAL   (Italy)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Health Sciences Center and Colorado Center for Bone Research   (United States)

^f NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; ZOLEDRONIC ACID; DRUG DERIVATIVE; ETIDRONIC ACID; IMIDAZOLE DERIVATIVE; ALKALINE PHOSPHATASE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LETTER; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; NOTE; ORAL DRUG ADMINISTRATION; BLOOD; DISEASE COURSE; REMISSION;

ADMINISTRATION, ORAL; ALENDRONATE; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; ETIDRONIC ACID; HUMANS; IMIDAZOLES; OSTEITIS DEFORMANS; ALKALINE PHOSPHATASE; DISEASE PROGRESSION; REMISSION INDUCTION;

EID: 28944454030     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc052601     Document Type: Letter

References (0)